Analyst Price Targets — STTK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 28, 2026 9:52 am | — | Piper Sandler | $15.00 | $4.34 | TheFly | Shattuck Labs initiated with an Overweight at Piper Sandler |
| December 1, 2025 11:08 am | — | H.C. Wainwright | $6.00 | $2.10 | TheFly | Shattuck Labs upgraded to Buy from Neutral at H.C. Wainwright |
| August 14, 2025 6:44 pm | Faisal Khurshid | Leerink Partners | $2.00 | $0.86 | TheFly | Shattuck Labs price target lowered to $2 from $4 at Leerink |
| August 15, 2024 6:15 am | Yigal Nochomovitz | Citigroup | $8.00 | $3.12 | TheFly | Shattuck Labs price target lowered to $8 from $9 at Citi |
| June 20, 2024 6:54 am | Joseph Pantginis | H.C. Wainwright | $16.00 | $4.59 | StreetInsider | Shattuck Labs (STTK) PT Lowered to $16 at H.C. Wainwright |
Latest News for STTK
Aberdeen Group plc increased its stake in Shattuck Labs, Inc. (NASDAQ: STTK) by 462.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 531,177 shares of the company's stock after purchasing an additional 436,673 shares during the period. Aberdeen Group plc owned approximately 0.84%
Shattuck Labs, Inc. (NASDAQ: STTK - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company.
The biotech published its final earnings report and business covering 2025. It posted a slightly narrower-than-expected net loss for the fourth quarter.
AUSTIN, Texas and DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today reported financial results for the fourth quarter and full…
AUSTIN, TX and DURHAM, NC, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for STTK.
U.S. House Trading
No House trades found for STTK.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.